Growth Hormone Secretagogue

CJC-1295

Long-acting GHRH analog with published human PK data, often stacked with ipamorelin.

GHRH receptor signalingGH/IGF-1 axisSomatostatin feedbackAlbumin-binding (DAC variant)

51 C+

Evidence Score

ⓘ For informational purposes only — not medical advice.

Score Breakdown

Overview

CJC-1295 is a synthetic analog of growth hormone-releasing hormone (GHRH) with a modified amino acid sequence for extended half-life. The DAC (Drug Affinity Complex) variant binds albumin, extending its half-life to ~8 days. It is commonly used in anti-aging and performance protocols, often stacked with ipamorelin.

Mechanism of Action

CJC-1295 binds the GHRH receptor on pituitary somatotrophs, stimulating GH synthesis and secretion. The DAC modification creates a sustained-release effect via albumin binding. When combined with a GHRP like ipamorelin, the synergistic effect on GH release is amplified (GHRH + GHRP synergy).

Evidence Base

Published human pharmacokinetic studies demonstrate sustained GH and IGF-1 elevation for 6–8 days post-injection (ConjuChem Biotechnologies). Phase II data exists. A notable safety incident (2017) involved adverse reactions at an Australian peptide clinic, raising awareness of dosing risks. No FDA approval.

Gene Pathway Detail

GHRH receptor activation drives GH gene (GH1) transcription in somatotrophs and downstream hepatic IGF-1 expression. The sustained GH elevation from CJC-1295 DAC produces more prolonged IGF-1 axis activation compared to pulsatile secretagogues. Biomeme can monitor IGF-1 pathway genes to quantify response duration.

mRNA Monitoring Insight

Like ipamorelin, IGF-1 axis gene expression provides the best transcriptomic readout. The sustained nature of CJC-1295 DAC may produce more detectable and consistent mRNA changes compared to short-acting secretagogues, making it potentially more amenable to transcriptomic monitoring.

Safety Considerations

Published human PK data provides some safety confidence. The 2017 Australian adverse event cluster highlighted risks of improper dosing. DAC variant creates sustained GH elevation that cannot be "turned off" once injected. Long-term safety of chronic GH axis stimulation is a concern. Not FDA-approved.

FAQ

What is the DAC in CJC-1295 DAC?

DAC stands for Drug Affinity Complex — a chemical modification that allows the peptide to bind to albumin in the blood, dramatically extending its half-life from ~30 minutes to ~8 days.

Quick Facts

Category: Growth Hormone Secretagogue
Score: 51/100 (C+)
Gene Pathways: 4 characterized

Sources

[1] CJC-1295 Pharmacokinetics — J Clin Endocrinol Metab 2006

Compare Others

Monitor Your Peptide Response.

Biomeme's transcriptomic platform tracks molecular pathway engagement so you know if your therapy is working.